quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Cancer Survivor

Drug Information

Target Indication

Cancer Survivor

Clinical Trial

Last updated: 9/11/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Related Pipeline

Heart Failure

Hepatitis C, Chronic

Hepatitis C

Rotavirus Gastroenteritis

HIV-1 Infection

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts